Severe myoclonic epilepsy in infancy: a systematic review and a meta-analysis of individual patient data. - Wikidata - awgldk - TriplyDB

Severe myoclonic epilepsy in infancy: a systematic review and a meta-analysis of individual patient data.

Severe myoclonic epilepsy in infancy: a systematic review and a meta-analysis of individual patient data.

http://www.wikidata.org/entity/Q31137269

about

Antiepileptic drugs for the treatment of infants with severe myoclonic epilepsy Antiepileptic drugs for the treatment of severe myoclonic epilepsy in infancy Antiepileptic drugs for the treatment of severe myoclonic epilepsy in infancy Targeted Treatment in Childhood Epilepsy Syndromes The pharmacologic treatment of Dravet syndrome Clinical review of genetic epileptic encephalopathies Uptake of systematic reviews and meta-analyses based on individual participant data in clinical practice guidelines: descriptive study.Screening of conventional anticonvulsants in a genetic mouse model of epilepsy.Stiripentol : in severe myoclonic epilepsy of infancy (dravet syndrome).A revisited strategy for antiepileptic drug development in children: designing an initial exploratory step.Incidence of Dravet Syndrome in a US Population.Epileptic encephalopathies in adults and childhood.Analysis of endocannabinoid signaling elements and related proteins in lymphocytes of patients with Dravet syndrome Synergistic GABA-enhancing therapy against seizures in a mouse model of Dravet syndrome.Audit of use of stiripentol in adults with Dravet syndrome Severe epilepsy syndromes of early childhood: the link between genetics and pathophysiology with a focus on SCN1A mutations.Managing severe epilepsy syndromes of early childhood.Current therapeutic procedures in Dravet syndrome."Epileptic encephalopathy" of infancy and childhood: electro-clinical pictures and recent understandings The use of recently approved antiepileptic drugs: use with caution, use in refractory patients or use as first-line indications?SCN1A mutations in Dravet syndrome: impact of interneuron dysfunction on neural networks and cognitive outcome.A hot topic: temperature sensitive sodium channelopathies.Specific safety and tolerability considerations in the use of anticonvulsant medications in children.Neurogenetic disorders and treatment of associated seizures.Population Pharmacokinetics of Stiripentol in Paediatric Patients with Dravet Syndrome Treated with Stiripentol, Valproate and Clobazam Combination Therapy.Pharmacological considerations in the use of stiripentol for the treatment of epilepsy.Stiripentol and vigabatrin current roles in the treatment of epilepsy.Antiepileptic drugs for the treatment of infants with severe myoclonic epilepsy.Treatment of Dravet Syndrome.Clinical and genetic factors predicting Dravet syndrome in infants with SCN1A mutations.The Impact of Next-Generation Sequencing on the Diagnosis and Treatment of Epilepsy in Paediatric Patients.Interactions between modulators of the GABA(A) receptor: Stiripentol and benzodiazepines Genetics of Epilepsy in Clinical Practice.Treatment of infants with epilepsy: Common practices around the world.Ranolazine selectively blocks persistent current evoked by epilepsy-associated Naν1.1 mutations.Dravet syndrome in Sweden: a population-based study.Reduced dendritic arborization and hyperexcitability of pyramidal neurons in a Scn1b-based model of Dravet syndrome.Comorbidities and predictors of health-related quality of life in Dravet syndrome.Variability of EEG-fMRI findings in patients with SCN1A-positive Dravet syndrome.Dynamic changes of depolarizing GABA in a computational model of epileptogenic brain: Insight for Dravet syndrome.

P2860

Q24186474-A43D877F-AA3F-439F-8476-FE8F55271101 Q24198031-A8E51C88-80E5-4925-8EBB-9F2C000820D9 Q24202411-6D42910E-19D6-4A22-96CC-ED50A7B927F2 Q26751431-3DFE0456-D47D-4FC8-A188-742B262E494F Q29013852-1E83C870-0084-45EB-9DBA-0A038114C115 Q30537230-89B64442-E4B2-453A-832A-E936DD6E0C74 Q30906124-AB6DA255-4416-4108-B952-4467B6E20851 Q33646252-661575E4-6B6E-40C6-AB86-48FDC68C0B80 Q34302354-DC31705B-8EB1-4866-ADB9-1B1A958C058B Q34560399-0EE71836-476E-41B3-AA0F-C3FC315A43EF Q36210601-24985CBF-E748-4658-BA49-8B2BECB883A9 Q36302381-61D6A08B-A7CA-4E3C-98BF-62F8762FB85C Q36719661-F5879E90-57BB-4F3E-B350-427DA6EEE96C Q36776559-7D3961F5-B2B6-4669-8250-769D4BA60E11 Q37505426-396E68AB-1480-4C02-A5A3-067939129E43 Q37576848-5EDB48DF-1F9D-4C4E-9B6F-6887EA6F35F3 Q37576853-C8DD8212-B9E7-401E-BF7F-333EE5002655 Q37866832-128E4013-9442-4E25-98AA-0E45A7373356 Q37883054-83895540-3B22-44F3-9D64-11776CF9A202 Q37957129-C4ED1283-5A82-44B2-B1FF-3307C4365EF0 Q37985147-CC5BC148-6BFC-4772-9920-1B17C60291E7 Q38014193-21B39A68-385A-4545-B1F4-642D16B0D07C Q38026034-6EB8234F-7EF8-4ABC-8D3D-FCD4FD8883C6 Q38080786-8CD69F17-2E45-4C5C-AB5B-33412141B99D Q38371961-22AEF92A-13CC-4044-A475-F7706E572E06 Q38738877-4985D900-21DF-437C-B770-5C7DFFADAA3A Q38757727-A4E58A6F-34B6-41B7-B622-4350C74A80E8 Q38776903-AE5C4849-5A0C-4216-B4F4-3426D7C26F63 Q38855474-F45E6CC0-7A2C-4E82-BC34-8B083789C85A Q38959338-783CE99A-B983-4088-9C3A-AC7F7D738BF6 Q39136036-4208E70D-BC22-4ECD-A698-AA2325D3DA25 Q39607659-A54E3EDA-BE01-4B8A-8B3E-7250C20F382A Q40597290-570B941C-51CA-4829-AFAA-7EB9C7EA7A24 Q40950744-D621250F-4EF8-49DD-85EF-E930792BC181 Q41121995-C0414C9E-3AE8-4A8E-97A2-E70C0676F97F Q41220933-81769AC0-8AD4-4D9F-A873-8F0DED1FB1E9 Q42655726-69198B6B-2E34-4409-B2FB-CEA76BB6FDEB Q44652755-2C307889-C878-4FDB-9F02-E01D4BFACD18 Q48168370-6B879266-7B49-42A3-BEDC-BF7A8878CA10 Q48703820-C649FBD5-B720-4092-8594-6B864E115F1E

P2860

Severe myoclonic epilepsy in infancy: a systematic review and a meta-analysis of individual patient data.

http://www.wikidata.org/entity/Q31137269

description

2007 nî lūn-bûn

@nan

2007 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Severe myoclonic epilepsy in i ...... is of individual patient data.

@ast

Severe myoclonic epilepsy in i ...... is of individual patient data.

@en

type

label

Severe myoclonic epilepsy in i ...... is of individual patient data.

@ast

Severe myoclonic epilepsy in i ...... is of individual patient data.

@en

prefLabel

Severe myoclonic epilepsy in i ...... is of individual patient data.

@ast

Severe myoclonic epilepsy in i ...... is of individual patient data.

@en

P1433

Q31137269-C0173890-BFA2-486E-B8DE-B317602C7F45

P1476

Q31137269-FDF2C854-8DBC-42B5-A13E-9F1EA741FF2B

P2093

Q31137269-08DC8F4C-3616-4952-BFB2-DAFC1979D211

Q31137269-1C44F322-2F68-47F5-BAC4-6CFC94F93D0E

Q31137269-2318F762-C1E7-4BFD-B35B-A1A9C29DC743

Q31137269-534312F3-9AD4-4626-A1F2-CAC85FCEA040

Q31137269-7B24563C-493A-4CD5-862C-C3BA2BA7E8A2

Q31137269-7D518DC7-A16E-4D11-9186-7878F39B84B0

Q31137269-888B3E0B-C241-45C5-84E5-3FA3D170463B

Q31137269-9CF2E0C2-D6C3-4C82-894A-6C277D8FDF67

Q31137269-AF1AC60E-99FF-46B6-95EB-C9FD72CE7808

Q31137269-BF5CF2CB-0E48-4F9C-8D6D-B07F4F409CCC

P2860

Q31137269-28ABCFF0-B7DD-4533-8F12-883222713A79

Q31137269-320AFF1F-1AC6-48BA-BF03-30046559909B

Q31137269-3C2CE786-D6A5-4F96-AB5F-C8A1CF042A7E

Q31137269-3FB32D1A-9AD7-47DF-8955-E498CACC38D9

Q31137269-498A6424-7B2A-48C0-A2DD-E42EDB860A7E

Q31137269-50B42337-1449-4189-8EA0-0309A83EED69

Q31137269-5DAC262F-E821-4D04-B433-2D919469F815

Q31137269-6294B42C-2FC2-4666-AA66-D5DB1CF1F36F

Q31137269-6F23C9F5-1466-4D46-8CB7-655555E7E63B

Q31137269-72645EB7-148E-4D7F-A08E-F4B246C71F9A

P304

Q31137269-D9CF63BA-7D95-4EFC-80F9-C10FBAF29993

P31

Q31137269-1a81599e-417e-4d21-a8c8-1a696a645f39

Q31137269-2E776C94-8E4C-4A82-93DA-F7681CDE550C

P356

Q31137269-CCEACE32-32CC-494F-9950-448914B93406

P433

Q31137269-88105BC5-D8F0-469A-897F-F4836A619FDA

P478

Q31137269-F02C7B5A-0C67-4D69-B2C6-95C2270A8973

P577

Q31137269-B7138CE4-A583-4957-83F5-474B99B9A60F

P5875

Q31137269-45092DAC-AEE9-4A2A-A7E5-4215D200114A

P698

Q31137269-26FDE03F-9784-447C-88DD-49F74FF4E9EE

P921

Q31137269-1C67B672-03FA-4F30-BEF2-80F28BD7806F

P356

J.1528-1167.2007.01423.X

P1433

P1476

Severe myoclonic epilepsy in i ...... is of individual patient data.

@en

P2093

Behrouz Kassaï

http://www.w3.org/2001/XMLSchema#string

Catherine Chiron

http://www.w3.org/2001/XMLSchema#string

Elisabeth Rey

http://www.w3.org/2001/XMLSchema#string

François Gueyffier

http://www.w3.org/2001/XMLSchema#string

Gérard Pons

http://www.w3.org/2001/XMLSchema#string

Julien Vincent

http://www.w3.org/2001/XMLSchema#string

Michel Cucherat

http://www.w3.org/2001/XMLSchema#string

Olivier Dulac

http://www.w3.org/2001/XMLSchema#string

Renzo Guerrini

http://www.w3.org/2001/XMLSchema#string

Ségolène Augier

http://www.w3.org/2001/XMLSchema#string

P2860

De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy

Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group

Spectrum of SCN1A mutations in severe myoclonic epilepsy of infancy

Stiripentol, a putative antiepileptic drug, enhances the duration of opening of GABA-A receptor channels

Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy

Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses

A comparison of summary patient-level covariates in meta-regression with individual patient data meta-analysis.

Individual patient- versus group-level data meta-regressions for the investigation of treatment effect modifiers: ecological bias rears its ugly head.

Comparison of evidence of treatment effects in randomized and nonrandomized studies.

Individual response to treatment: is it a valid assumption?

P304

343-348

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1528-1167.2007.01423.X

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

49

http://www.w3.org/2001/XMLSchema#string

P577

2007-11-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5819731

http://www.w3.org/2001/XMLSchema#string

P698

18028411

http://www.w3.org/2001/XMLSchema#string

P921